Insmed reported $377.11M in Debt for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Acelrx Pharmaceuticals ACRX:US $ 20.05M 1.94M
Alexion Pharmaceuticals ALXN:US $ 143.2M 2418.8M
Alimera Sciences ALIM:US $ 43.02M 1.59M
Arena Pharmaceuticals ARNA:US $ 44.58M 1.03M
Biomarin Pharmaceutical BMRN:US $ 1076.13M 5.89M
Cytokinetics CYTK:US $ 137.39M 1.68M
Dynavax Technologies DVAX:US $ 179.89M 0.08M
Flexion Therapeutics FLXN:US $ 223.36M 344K
Heron Therapeutics HRTX:US $ 7.56M 0.5M
Insmed INSM:US $ 377.11M 5M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NVS:US $ 35769M 2030M
Regeneron Pharmaceuticals REGN:US $ 2696.7M 1M
Sarepta Therapeutics SRPT:US $ 1091.11M 98.62M
Seattle Genetics SGEN:US $ 0M 0M
Ultragenyx Pharmaceutical RARE:US $ 0M 1.16M
Vertex Pharmaceuticals VRTX:US $ 572.86M 8.62M